EXTENDED SPECTRUM BETA-LACTAMASE (ESBL) PREVALENCE IN BACTERIA ISOLATED FROM URINE SAMPLES
Keywords:
Prevalence, ESBL E. coli/ K. Pneumoniae, UTIAbstract
Urinary tract infections (UTI) due to E. coli are the most common infectious diseases. Extended spectrum beta-lactamases (ESBLs) are clinically important because they destroy cephalosporins - antibiotics which are used as first line agents in critically ill patients, including those with intra-abdominal infections, pneumonias and bacteremia. The aim of this study is to present the prevalence of ESBL E. coli/K. pneumoniae UTI through a retrospective review of medical records in the period from 2019 to 2023.
This was a retrospective study conducted at the Institute of Public Health (IPH) of the Republic of North Macedonia, in which the prevalence of ESBL E. coli/ K. pneumoniae UTI was elaborated covering the period from 2019 to 2023.
The analysis by year at the national level, presented in Table 1, shows that most of the reports were registered in 2019 - 134 or 32.1%, while the smallest number were reported in 2020 - 31 or 7.4%. The analysis of demographic data in terms of gender shows that a cumulatively higher number of reports at the national level was registered among women - 269 or 64.5%. If data from the IPH are analyzed according to this indicator, 46 women (82.1%) and 10 men (17.9%) were registered.
In conclusion, the current study indicated a significant rate of infection with ESBL-producing Gram-negative bacilli in patients with UTI.
References
Vachvanichsanong P, McNeil EB, Dissaneewate P. Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections. Epidemiol Infect 2020; 149: e12. doi: 10.1017/S0950268820003015.
Antimicrobial resistance surveillance in Europe 2023 - 2021 data. Stockholm: European Centre for Disease Prevention and Control and World Health Organization; 2023.
Omar MH, Kilale AM, Rashid HK, Mwakapeje ER, Onoka IM, Gimbi AA. Prevalence and risk factors for extended-spectrum β-lactamase producing antimicrobial-resistant E. coli in urinary tract infections among inpatients in the tertiary hospitals in Zanzibar (Tanzania): a prospective cross-sectional study. Pan Afr Med J 2024; 47: 193. doi: 10.11604/pamj.2024.47.193.37920.
Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995 Jun;39(6):1211-33. doi: 10.1128/AAC.39.6.1211.
Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8(4): 557-584. doi: 10.1128/CMR.8.4.557.
Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14(4): 933-951. doi: 10.1128/CMR.14.4.933-951.2001.
Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007; 59(2): 165-174. doi: 10.1093/jac/dkl483.
Carattoli A. Animal reservoirs for extended-spectrum β-lactamase producers. Clin Microbiol Infect 2008; 14(Suppl1): 117-123. doi: 10.1111/j.1469-0691.2007.01851.x.
Bush K, Bradford PA. Epidemiology of β-Lactamase-Producing Pathogens. Clin Microbiol Rev 2020; 33(2): e00047-19. doi: 10.1128/CMR.00047-19.
Naas T, Poirel L, Nordmann P. Minor extended-spectrum β-lactamases. Clin Microbiol Infect 2008; 14(Suppl1): 42-52. doi: 10.1111/j.1469-0691.2007.01861.x.
EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Version 1.0. December 2013.
Gyawali S, Shankar PR, Poudel PP, Saha A. Knowledge, attitude and practice of self-medication among basic science undergraduate medical students in a medical school in western Nepal. J Clin Diagn Res 2015; 9(12): FC17-22. doi: 10.7860/JCDR/ 2015/16553.6988.
Shankar PR, Partha P, Shenoy N. Self-medication and non-doctor prescription practices in Pokhara valley, Western Nepal: a questionnaire-based study. BMC Fam Pract 2002; 3: 17. doi: 10.1186/1471-2296-3-17.
Gharavi MJ, Zarei J, Roshani-Asl P, Yazdanyar Z, Sharif M, Rashidi N. Comprehensive study of antimicrobial susceptibility pattern and extended spectrum beta-lactamase (ESBL) prevalence in bacteria isolated from urine samples. Sci Rep 2021; 11(1): 578. doi: 10.1038/s41598-020-79791-0.
Ramatla T, Mafokwane T, Lekota K, Monyama M, Khasapane G, Serage N, et al. "One Health" perspective on prevalence of co-existing extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae: a comprehensive systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 2023; 22(1): 88. doi: 10.1186/s12941-023-00638-3.
Mohamed Al-Agamy MH, El-Din Ashour MS, Wiegand I. First description of CTX-M beta-lactamase-producing clinical Escherichia coli isolates from Egypt. Int J Antimicrob Agents 2006; 27(6): 545-548. doi: 10.1016/j.ijantimicag.2006.01.007.
